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Abstract
RAD21 encodes a key component of the cohesin complex, and variants in RAD21 have been associated with Cornelia de 
Lange Syndrome (CdLS). Limited information on phenotypes attributable to RAD21 variants and genotype–phenotype 
relationships is currently published. We gathered a series of 49 individuals from 33 families with RAD21 alterations [24 
different intragenic sequence variants (2 recurrent), 7 unique microdeletions], including 24 hitherto unpublished cases. 
We evaluated consequences of 12 intragenic variants by protein modelling and molecular dynamic studies. Full clinical 
information was available for 29 individuals. Their phenotype is an attenuated CdLS phenotype compared to that caused by 
variants in NIPBL or SMC1A for facial morphology, limb anomalies, and especially for cognition and behavior. In the 20 
individuals with limited clinical information, additional phenotypes include Mungan syndrome (in patients with biallelic 
variants) and holoprosencephaly, with or without CdLS characteristics. We describe several additional cases with pheno-
types including sclerocornea, in which involvement of the RAD21 variant is uncertain. Variants were frequently familial, 
and genotype–phenotype analyses demonstrated striking interfamilial and intrafamilial variability. Careful phenotyping is 
essential in interpreting consequences of RAD21 variants, and protein modeling and dynamics can be helpful in determining 
pathogenicity. The current study should be helpful when counseling families with a RAD21 variation.
Introduction
RAD21 (ENSG00000164754; OMIM *606462) is a key 
component of the cohesin complex and it forms a tri-partite 
ring together with SMC1A and SMC3 (Fig. 1 and Suppl. 
Fig. S1). The cohesin complex is a major modulator of chro-
mosome structure, is involved in regulating chromosome 
segregation during mitosis, DNA repair and chromatin con-
densation, and plays an important role in gene transcription 
during interphase and cellular homeostasis (Kamada and 
Barilla 2018; Mullenders et al. 2015; Watrin et al. 2016). 
RAD21 has been implicated in additional processes includ-
ing mediation of epigenetic silencing and induction of apop-
tosis (Fisher et al. 2017; Pati et al. 2002). Variants in genes 
encoding various structural or functional components of the 
cohesin complex, including RAD21, SMC1A, SMC3, BRD4, 
STAG1/2, NIPBL, HDAC8, WAPL, ANKRD11 and in single 
individuals PDS5A and ESPL1, have been implicated in Cor-
nelia de Lange Syndrome (CdLS) (Ansari et al. 2014; Kline 
et al. 2018; Woods et al. 2014; Yuan et al. 2019). RAD21 
spans ~ 29 Kb and has 14 exons (13 coding, 1 noncoding) 
that together encode a protein of 631 amino acids (McKay 
et al. 1996).
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RAD21 variants are found in a minority of CdLS 
patients. To date, nine missense variants and 5 microde-
letions have been reported in CdLS patients (Kline et al. 
2018). CdLS is characterized by distinct facial features, 
growth delay, microcephaly, limb reduction defects, intel-
lectual disability (ID) and behavioral problems, especially 
self-injurious behavior (SIB) and autism spectrum disor-
der (ASD) (Kline et al. 2018). RAD21 variants have also 
been associated with sclerocornea (Zhang et al. 2019) and 
Mungan syndrome (Chronic Idiopatic Intestinal Pseudoo-
bstruction; OMIM #611376, in patients with biallelic 
RAD21 variants) (Bonora et al. 2015; Mungan et al. 2003), 
each in a single family in which no remarks on CdLS fea-
tures were made in the report. Loss of function-variants in 
cohesin genes including RAD21 were found in individu-
als with holoprosencephaly of whom some demonstrated 
CdLS features as well (Kruszka et al. 2019).
RAD21 is positioned on chromosome 8q24.11, between 
TRPS1 (Tricho-Rhino-Phalangeal syndrome type 1; 
OMIM *604386) and EXT1 (Multiple Exostoses type 
1; OMIM *608177). Several microdeletions involving 
RAD21 encompass genes next to RAD21 (contiguous gene 
syndrome), complicating attribution to RAD21 of the phe-
notype (Deardorff et al. 2012; Pereza et al. 2012; Wuyts 
et al. 2002). TRPS type 2 or Langer-Giedion syndrome 
(OMIM #150230) involves TPRS1, RAD21 and EXT1, 
and the facial phenotype is mainly determined by loss of 
TRPS1, whereas the bony abnormalities arise from the loss 
of EXT1 (Maas et al. 2015).
Based on the small case series of CdLS patients with 
RAD21 variants reported so far, face and limb manifestations 
of CdLS seem to be less pronounced compared to individu-
als with variants in the other cohesin complex genes, and the 
impact on cognitive functioning seems attenuated, without 
clear genotype–phenotype correlation (Kline et al. 2018; 
Minor et al. 2014). Here, we report on a case series of 49 
patients from 33 families with RAD21 alterations, including 
all previously published cases with sequence variants, most 
of which with updated clinical data. We included 24 hith-
erto unpublished cases. We present genotype data, evaluate 
the pathogenicity of intragenic variants by a combination of 
phenotype, protein modelling, and molecular dynamic stud-
ies, and provide information on clinical phenotype, includ-
ing cognitive and behavioral functioning, interfamilial and 
intrafamilial variability, and genotype–phenotype associa-
tions. We compare the RAD21 phenotype to that of patients 
with NIPBL and SMC1A variants.
Results
We identified 219 cases with RAD21 variants, of which 
49 patients from 33 families were included in this study 
(Tables 1 and S1). We describe in Table S6 those excluded 
cases that still may be of interest such as published cases 
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Fig. 1  Presently reported RAD21 variants. a RAD21 (horizontal bar) 
has three binding domains: SMC3 (p.1–103), STAG1/2 (p.362–403) 
and SMC1A (p.558–628). Sizes of the binding domains are not 
shown to scale. Truncating RAD21 variants are shown above, and 
missense mutations and in-frame deletions are shown below the pro-
tein representation. Variants for which protein modelling is available, 
are marked in bold. F family number. The horizontal black line rep-
resents the inframe deletion p.(Asp541_Gln568del). ClinVar vari-
ants which are reported in the ClinVar database and could be inves-
tigated for pathogeneity with protein modelling (see supplementary 
Table  S6). b Genomic region showing the microdeletions including 
RAD21 
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with involvement of other morbid genes (Deardorff et al. 
2012; Maas et al. 2015; Pereza et al. 2012; Wuyts et al. 
2002; Yuen et al. 2015), variants reported as variant of 
unknown significance (VUS) that remained with unknown 
significance subsequent to re-evaluation, and cases for 
whom the relationship between phenotype and RAD21 
variant could not be confirmed(Kruszka et al. 2019; Zhang 
et al. 2019).
The 49 patients can be divided into two groups: cohort 
A includes 29 patients (22 families) with sufficient clinical 
data; and cohort B includes 20 patients (11 families) with 
incomplete data. Of the 49 cases, 24 are new. Twenty-
five were previously published (Ansari et al. 2014; Bonora 
et al. 2015; Boyle et al. 2017; Deardorff et al. 2012; Dor-
val et al. 2019; Gudmundsson et al. 2018; Kruszka et al. 
2019; Lee et al. 2014; Martinez et al. 2017; McBrien et al. 
2008; Minor et al. 2014; Yuan et al. 2019), and for 19 of 
these clinical data could be updated (Table 1). Patients 
originated from Australia, Belgium, Canada, Denmark, 
Germany, Italy, Netherlands, Spain, Sweden, Switzerland, 
Turkey, United Kingdom and United States.
Genotype
The 33 families harbor 31 different variants: seven 
unique copy number variations (CNVs) and 24 intra-
genic sequence variants. Two of the latter were recurrent 
[p.(Cys585Arg) and p.(Arg586*), each found in 2 fami-
lies (Table 1, Fig. 1)]. A relatively large proportion of the 
cases are familial (nine out of 21 index cases for whom 
inheritance could be established). The seven CNVs were 
all deletions, six of which included other genes in addition 
to RAD21. Of the 24 different sequence variants, 13 are 
predicted be truncating (2 nonsense, 2 splice site and 9 
frameshift variants), and these are scattered throughout the 
gene. Three of the variants are in-frame deletions, two of 
which affect a single amino acid, while the 665 bp deletion 
includes the whole exon 13. The missense variants tend 
to cluster at the functional domains of the protein. Some 
variants in cohort B may be recurrent but sufficient data 
are lacking to confirm this (Table S6).
Evaluation of pathogenicity of RAD21 variants using 
molecular dynamic analyses
For 12 intragenic variants (ten missense variants and two 
3 bp in-frame deletions, from individuals in cohort A, 
B and Table S6) it was possible to carry out structural 
analysis, as their substituted residues are located in one 
of the domains for which 3D arrangement can be mod-
eled (RAD21-SMC3 domain, RAD21-STAG domain and 
RAD21-SMC1A domain, Fig. 2; Figs. S2-3). Interactions 
between RAD21 and its binding partners are shown in 
Fig. S1.
Modeled missense variants within the RAD21‑SMC3 
domain (residues 18–87 harboring Arg65Gln), 
and RAD21‑STAG domain (residues 321–392 harboring 
Ser345Pro, Pro355Leu and Pro376Arg)
Substitution of Arg65 with Gln (Arg65Gln) is a semi-con-
servative variation that did not promote detectable structural 
or dynamic changes in the complex. The Ser345Pro variant 
impairs RAD21 and STAG1/2 interactions due to promotion 
of a de novo curved small alpha-helix segment that binds 
to the pre-existing alpha helix, which separates from the 
surface of STAG2. No structural or dynamic effects of Pro-
355Leu or Pro367Arg on RAD21 itself could be observed. 
Nevertheless, Pro376Arg does promote the formation of a 
new salt bridge between RAD21 and STAG2, which is pre-
dicted to cause over-stabilization of the interaction between 
the two proteins.
Modeled missense variants within the RAD21‑SMC1A 
domain (residues 543–628 harboring Gly575Ala, 
Cys585Arg, Arg586Gln, Gln592del, Phe600del, Leu603Pro, 
Ser618Gly, and Ala622Thr)
Four of the eight variants in this domain (Cys585Arg; Arg-
586Gln; Gln592del; Leu603Pro) are predicted to cause 
a structural effect. Arg586Gln destabilizes the RAD21-
SMC1A domain by loss of a salt bridge between Arg586 
and Glu577, and the altered position of Glu577 adds 
an additional negative charge to the RAD21 surface of 
RAD21-SMC1A. Cys585Arg has a similar effect, inter-
acting with Glu583 and causing Arg586 to lose its contact 
with Glu577. The MD simulation shows that both Gln592del 
and Leu603Pro, but not Phe600del, affect the positioning of 
SMC1A-Asn35 at the ATPase site 1 by changing the posi-
tion of Lys605.
Phenotype
Physical features
Individual CdLS scores and major and minor anomalies 
in cohort A are provided in Table S2-3. Clinical features 
of cohort A are compared to those of NIPBL and SMC1A 
cohorts in Table 2 and illustrated in Fig. 3 and Fig. S4. Clini-
cal information for cohort B is available in supplemental 
materials S5 and will not be discussed further in the text, as 
clinical data are limited. We mention data in the text only if 
not represented in the tables.
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Table 1  Molecular findings of the presently reported series of individuals with RAD21 variants
PID Reference Source CdLS 
 scorea
Exon/
intron
Nucleotide change Predicted amino 
acid change
Type Inheritance
Cohort A—sufficient clinical data
 F1 Martinez 2017 Updated 9 Exon 2 c.68G > A p.(Trp23*) Nonsense De novo
 F2 Clinvar New ≥ 7 Exon 2 c.194G > A p.(Arg65Gln) Missenseb
 F3a Ansari 2014 P1 Updated ≥ 10 Intron 3 c.274 + 1G > A Splice site Familial 
(paternal)
 F4 Minor 2014 P2 Updated 12 Exon 6 c.592_593dupAG p.(Ser198Argfs*6) Frameshift
 F5 Unpublished New 9 Exon 6 c.617_620del p.(Ile206Thrfs*3) Frameshift De novo
 F6a Boyle 2017 IV.16 Updated 12 Exon 7 c.704delG p.(Ser235Ilefs*19) Frameshift Familial 
(maternal)
 F6b Boyle 2017 III.1 Updated 10 Exon 7 c.704delG p.(Ser235Ilefs*19) Frameshift Familial 
(parents not 
tested)
 F6c Boyle 2017 III.2 Updated 9 Exon 7 c.704delG p.(Ser235Ilefs*19) Frameshift Familial 
(parents not 
tested)
 F6d Boyle 2017 III.5 Updated 9 Exon 7 c.704delG p.(Ser235Ilefs*19) Frameshift Familial 
(parents not 
tested)
 F6e Unpublished New 12 Exon 7 c.704delG p.(Ser235Ilefs*19) Frameshift Familial 
(maternal)
 F7 Dorval 2019 Original 
data
≥ 11 Exon 9 c.943_946del p.(Glu315Glnfs*9) Frameshift De novo
 F8 Deardorff 2012 P5 Original 
data
≥ 10 Exon 9 c.1127C > G p.(Pro376Arg) Missenseb De novo
 F9 Kruszka 2019 P14 Updated 13 Exon 10 c.1217_1224del p.(Lys406Argfs*4) Frameshift De novo
 F10 Unpublished New 10 Exon 11 c.1382C > T p.(Thr461Ile) Missense Familial 
(paternal)
 F11a Minor 2014 P1 Updated 8 Exon 13 c.1621-
388_1704 + 193del
p.(Asp541_
Gln568del)
Inframe 
deletion
Familial 
(maternal)
 F11b Minor 2014 mother P1 Updated ≥ 5 Exon 13 c.1621-
388_1704 + 193del
p.(Asp541_
Gln568del)
665 bp 
inframe 
deletion
 F12 Unpublished New 13 Exon 13 c.1635del p.(Gly-
547Alafs*65)
Frameshift De novo
 F13 Deardorff 2012, P6 Orginal data ≥ 12 Exon 14 c.1753T > C p.(Cys585Arg) Missenseb De novo
 F14a Unpublished New 12 Exon 14 c.1753T > C p.(Cys585Arg) Missenseb Familial 
(parents not 
tested)
 F14b Unpublished New ≥ 10 Exon 14 c.1753T > C p.(Cys585Arg) Missense Familial 
(parents not 
tested)
 F15 Unpublished New ≥ 12 Exon 14 c.1756C > T p.(Arg586*) Nonsense
 F16a Unpublished New 10 Exon 14 c.1756C > T p.(Arg586*) Nonsense Familial 
(paternal)
 F16b Father, unpublished New ≥ 10 Exon 14 c.1756C > T p.(Arg586*) Nonsense
 F17 Gudmunsson 2019 Updated 8 Exon 14 c.1774_1776del p.(Gln592del) Inframe 
 deletionb
De novo
 F18 Unpublished New 9 Exon 14 c.1800_1802del p.(Phe600del) Inframe 
 deletionb
 F19 Deardorff 2012 P4 Original 
data
≥ 12 Whole 
gene
arr[hg19] 8q23
.3q24.11(116880827–118875305)x1
2 Mb dele-
tion
 F20 Unpublished New ≥ 12 Whole 
gene
arr[hg19] 8q23
.3q24.11(116915114–119171074)x1
2.3 Mb 
deletion
De novo
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Table 1  (continued)
PID Reference Source CdLS 
 scorea
Exon/
intron
Nucleotide change Predicted amino 
acid change
Type Inheritance
 F21 Deardorff 2012 P2, 
McBrein 2008
Original 
data
≥ 12 Whole 
gene
arr[hg19] 8q23
.3q24.12(117571728–119260904)x1
1.7 Mb 
deletion
De novo
 F22 Unpublished New 12 Exons 
1–9
arr[hg19] 8q24.11(117866471– 
117893495)x1
27 kb dele-
tion
Cohort B—insufficient clinical data
 F3b Ansari 2014 Updated Intron 3 c.274 + 1G > A n/a Splice site
 F23 Decipher 271431 New Exon 2 c.16T > G p.(Phe6Val) Missense De novo
 F24 Unpublished New Exon 2 c.85delinsCCT p.(Lys29Profs*10) Frameshift
 F25a Decipher 272901 New Exon 9 c.951del p.(Ala318Profs*7) Frameshift Familial 
(paternal)
 F25b Decipher 272901 father New Exon 9 c.951del p.(Ala318Profs*7) Frameshift
 F26 Decipher 275402 New Exon 9 c.1033T > C p.(Ser345Pro) Missenseb De novo
 F27a Yuan 2018 P2 Updated Intron 
10
c.1161 + 1G > A Splice site Familial 
(maternal)
 F27b Yuan 2018 mother P2 Updated Intron 
10
c.1161 + 1G > A Splice site
 F28a Kruszka 2019 P12/Yuan 
2019 P1
Updated Exon 12 c.1550dupC p.(Glu-
518Argfs*19)
Frameshift Familial 
(paternal)
 F28b Kruszka 2019 P12 
father/Yuan 2019 P1 
father
Updated Exon 12 c.1550dupC p.(Glu-
518Argfs*19)
Frameshift
 F29 Lee 2014 P76 Original 
data
Exon 14 c.1808T > C p.(Leu603Pro) Missenseb De novo
 F30a Bonora 2015 IV.9 Updated Exon 14 c.[1864G > A]; 
[1864G > A]
p.(Ala622Thr) Missenseb Familial (both 
parents)
 F30b Bonora 2015 IV.10 Updated Exon 14 c.[1864G > A]; 
[1864G > A]
p.(Ala622Thr) Missenseb Familial (both 
parents)
 F30c Bonora 2015 IV.11 Updated Exon 14 c.[1864G > A]; 
[1864G > A]
p.(Ala622Thr) Missenseb Familial (both 
parents)
 F30d Unpublished New Exon 14 c.[1864G > A] p.(Ala622Thr) Missenseb Familial (nos)
 F30e Unpublished New Exon 14 c.[1864G > A] p.(Ala622Thr) Missenseb Familial (nos)
 F30f Unpublished New Exon 14 c.[1864G > A] p.(Ala622Thr) Missenseb Familial (nos)
 F31 ClinVar New Whole 
gene
arr[hg19] 8q23.3-24.11(116902507–
118942698)x1
2 Mb 
deletion; 
includes 
several 
genes
 F32 ClinVar New Whole 
gene
arr[hg19] 8q23.3-24.11(117509968–
118391406)x1
880 kb 
deletion; 
includes 
several 
genes
 F33 ClinVar New Whole 
gene
arr[hg19] 8q24.11(117714768– 
119072307)x1
1.4 Mb 
deletion; 
includes 
several 
genes
Cohort A: detailed clinical data available, including information on all cardinal CdLS features; cohort B: insufficient clinical data available
F family number, P patient number in the respective publication, nos not otherwise specified
a Based on (Kline et al. 2018); ≥ defines at least (minor criteria missing). Score < 4 is insufficient to indicate molecular testing for CdLS; score 
4–8 indicates molecular testing for CdLS indicated; score 9–10 indicates non-classic CdLS; score 11 or higher indicates classic CdLS
b Variants investigated with protein modelling
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All patients in cohort A (age range 0–61 years, median 9 
years, mean 18 years; 15 males) had CdLS scores of at least 
five, sufficient to warrant molecular genetic testing for CdLS. 
In about 60% of index cases (13/21 index cases in which this 
was specified) CdLS was suspected prior to testing. There 
was no gender difference in CdLS scores. No RAD21 variant 
would have been missed using the CdLS consensus criteria 
for molecular studies (Kline et al. 2018). Clinical scores of 
patients with CdLS suspected prior to testing (median 11.5; 
range 8–13) were higher than those not suspected to have 
CdLS (median 9.5; range 5–13).
Cognition, development and behavior
Cognitive functioning, developmental milestones and behav-
ioral functioning in the RAD21 group are attenuated com-
pared to the NIPBL and SMC1A groups (Tables 3 and S4). 
The majority of RAD21 patients (16/29, 55%) have normal 
or mildly impaired cognitive functioning (SMC1A group 
32%; NIPBL group 7%) (Huisman et  al., 2017; Mulder 
et al., 2019). In all three groups, there is a trend towards 
more language-based problems than motor-based problems 
in development. Still, all RAD21 patients aged 3 years and 
above were able to use some words. There was no correla-
tion between the severity of cognitive impairment in RAD21 
patients and presence of microcephaly (prenatal, postnatal, 
or both; data not shown).
14/25 RAD21 patients (56%) with sufficiently available 
information on behavior had problems, mainly features of 
anxiety, ADHD, ASD, and obsessive–compulsive behavior. 
ASD related problems, aggression and SIB were less preva-
lent compared to the SMCIA and NIPBL groups.
Genotype–phenotype comparisons in cohort A
Microdeletions versus intragenic variants
There was a trend towards higher CdLS scores and more 
frequently impaired growth parameters in patients with 
microdeletions compared to those with intragenic variants, 
but no differences were apparent in frequency of major 
malformations or cognitive and behavioral problems. We 
refrained from statistical analyses as small numbers would 
make results too unreliable and less useful. Exostoses, 
related to EXT1 haploinsufficiency, likely caused the upper 
limb anomalies.
Truncating versus non‑truncating sequence variants
There was no difference in CdLS scores or growth param-
eters between individuals with truncating and those with 
non-truncating sequence variants (median 10; range 9–13 
and median 9.5; range 5–12, respectively).
Malformations and genotype
For 12/15 patients with intragenic variants and major mal-
formations or health problems, the variant was located in 
a protein-binding domain (F2, F3a, F8, F9, F11a, F11b, 
F12, F14a, F14b, F16a, F17, F18). As numbers are small it 
remains uncertain whether this is truly an association. The 
types of major malformations did not differ.
Intrafamilial variation
The intrafamilial variation can be considerable (Tables S1, 
S3-4; Fig. 3), especially in cognition and behavior. Through 
obvious ascertainment bias cognition is more frequently 
impaired in index cases. Several families include patients 
with ID and patients with apparently normal cognitive func-
tioning. The intrafamilial variation cannot be explained by 
mosaicism in most families.
Discussion
We report on RAD21 variants in 49 individuals, some with 
sufficient clinical data (cohort A), others with limited clini-
cal data (cohort B). RAD21 variants are frequently familial, 
often unique, and without obvious hotspots for variants or 
microdeletions breakpoints, although missense variants tend 
to cluster around protein binding domains.
RAD21 missense variants and their predicted effect 
on protein function
The structural and functional analysis indicated that at least 
six out of twelve modeled RAD21 missense variants are 
likely pathogenic (Ser345Pro, Pro367Arg, Cys585Arg, Arg-
586Gln (reported as a VUS), Gln592del and Leu603Pro). 
If phenotype data and literature/database information are 
taken into account, three more RAD21 modeled missense 
variants are likely pathogenic (Arg65Gln (reported as VUS), 
Phe600del, Ala622Thr).
The Arg65 is located within the RAS21-SMC3 domain 
in the close proximity of Tyr67, and altering the kinase/
phosphatase recognition motif Arg-X-Tyr around Tyr67 
may affect the phosphorylation-based regulation of RAD21 
(Amanchy et al. 2011; Hoque and Ishikawa 2001; Hornbeck 
et al. 2015; Li et al. 2009). In addition, a contact between 
the PDS5 protein and the RAD21-SMC3/SMC3-head com-
plex is involved in the topological entrapment of DNA by 
cohesin (Guacci et al. 2019). As Arg65 is located towards 
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the solvent, Arg65Gln may impact the RAD21-PDS5 rec-
ognition and, thus, disturb their interaction.
The interaction between RAD21 and STAG1/2 is cru-
cial for the proper functioning of the cohesin complex 
(Guacci et al. 2019), and both impairing (Ser345Pro) or 
over-stabilizing (Pro367Arg) variants within the RAD21-
STAG domain are predicted to cause dysfunction of the 
complex, presumably through affecting the continuous 
cycle of formation and disengagement of the cohesin ring 
(Marcos-Alcalde et al. 2017).
The structural model of the RAD21-SMC1A domain 
rationalizes the key function of RAD21 in the ATPase 
reaction at the SMC1A/SMC3 head, which is pivotal to 
the opening of the cohesin ring, and thus the cyclic process 
(Marcos-Alcalde et al. 2017). The Cys585Arg and Arg-
586Gln variants destabilize the RAD21-SMC1A domain; 
and Gln592del and Leu603Pro (but not Phe600del) dis-
turb the cyclic process through the dislocation of Lys605. 
Although the Phe600del variant does not seem to affect 
RAD21 structure, it leads to a classical CdLS phenotype 
without variants in additional known CdLS genes (using 
a targeted gene panel). Thus, it does seem likely patho-
genic. Unfortunately, the crystal structure of RAD21 is 
not available for other domains or interacting partners such 
as WAPL and PDS5, but earlier molecular studies provide 
additional information for other missense variants.
The importance of the regulation of the interaction 
between RAD21-SMC1A and SMC1A/SMC3 head is 
demonstrated by the several residues involved in phospho-
rylation and ubiquitination in the RAD21-SMC1A domain 
(Hegemann et al. 2011; Hoque and Ishikawa 2001; Horn-
beck et al. 2015). Ala622 is positioned next to Thr623, a 
substrate for protein phosphorylation by PLK1 (Hornbeck 
et al. 2015; Tsai et al. 2015). A pathogenic effect of vari-
ant Ala622Thr is supported by studies showing decreased 
bowel transit and loss of enteric neurons in zebrafish 
with Ala622Thr knockdown through morpholinos and by 
patients with biallelic Ala622Thr variants and Mungan 
syndrome with CIPO (chronic intestinal pseudo-obstruc-
tion) (Bonora et al. 2015). The heterozygous members of 
this family had some clinical features of the CdLS spec-
trum, but as it was not possible to retrieve further clinical 
data, it remains uncertain whether they have a full CdLS 
phenotype, and whether this variant can lead to a pheno-
type in heterozygous form.
For two additional variants that could not be modeled, 
the literature supports that they are likely pathogenic. Phe6 
is found close to Ser9, a phosphorylation site described 
in the human proteome (Gauci et al. 2009; Guacci et al. 
2019). The Phe6Val variant (reported as aVUS) would 
modify the kinase/phosphatase recognition motif, thus 
affecting the protein behavior. Similarly, as residue Thr461 
is flanked by Ser residues (Ser459 and Ser466), both 
implicated in phosphorylation-regulated dissociation of 
cohesin from chromosome arms (Hauf et al. 2005; Horn-
beck et al. 2015), it may modify the kinase/phosphatase 
recognition motif.
Clinical phenotype
Physical phenotype
RAD21 variants can lead to a CdLS phenotype (RAD21-
CdLS). The (limited) available information of individuals 
from cohort B suggests that biallelic RAD21 variants can 
also lead to Mungan syndrome and monoallelic RAD21 
variants to holoprosencephaly (like one case in cohort A) 
and possibly schizophrenia, although in the latter the asso-
ciation may be a spurious coincidence. In Table S6 we 
describe several additional cases with phenotypes includ-
ing sclerocornea and schizophrenia, in which pathogenic-
ity of the RAD21 variant is debatable. Due to incomplete 
information it remains uncertain whether these individuals 
are also showing CdLS characteristics. Indeed, when we 
succeeded in obtaining further clinical information, sev-
eral individuals turned out to show CdLS characteristics 
not mentioned in the publication (for instance in the family 
with Mungan syndrome). Additionally, one may speculate 
that phenotypes are also attributable (possibly in addition 
to the RAD21 variant) to variants in other genes.
Comparison to phenotypes of NIPBL and SMC1A variants
In patients with sufficient clinical data available (cohort A) 
most features associated with CdLS are present. However, 
the prevalence of features is lower compared to those in the 
SMC1A and NIPBL cohort, and the degree of severity is typ-
ically less. Severe visual impairment and diaphragmatic her-
nias are rare in RAD21 patients, and feeding difficulties are 
uncommon. RAD21 patients less frequently have increased 
body hair (hirsutism, bushy eyebrows, low scalp hair lines), 
major limb malformations are not reported, and hands and 
feet are generally of normal size. Still, minor anomalies of 
hands and feet are common, such as fetal pads, abnormal 
flexion crease patterns, and camptodactyly. Patients with 
RAD21 variants have generally less impaired growth at birth, 
and short stature and microcephaly develop postnatally. Pre-
natal microcephaly has been demonstrated to be a predictor 
of more severe cognitive impairment in CdLS in the pre-
molecular era (Hawley et al. 1985) but this does not hold 
for RAD21 patients. Frequency and severity of congenital 
heart defects are similar to those in the NIPBL and SMC1A 
cohorts. Gastro-esophageal reflux is similar in frequency but 
in RAD21 it is typically mild and restricted to early child-
hood. No RAD21 patients exhibit a Rett-like phenotype as 
can occur in a subgroup of patients with SMC1A variants 
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(Huisman et al. 2017). The CdLS score remains a reliable 
tool, and the present study does not call for an adjustment 
of the diagnostic advice from the CdLS guidelines (Kline 
et al. 2018).
Unusual anomalies in the RAD21 cases are vertebral 
anomalies (clefts and hemivertebrae). There is a single 
individual with a NIPBL variant and Klippel–Feil anomaly 
(personal observation RCH), and upper cervical spine mal-
formations have been reported in other patients with NIPBL 
variants as well (Bettini et al. 2014). Malformations of 
structures derived from the embryonic foregut are relatively 
frequent in RAD21 patients and have only rarely been 
described in CdLS (Hamilton et al. 2014; Kang et al. 2018; 
Mende et al. 2012). Holoprosencephaly spectrum anomalies 
have been linked to several cohesin genes (Kruszka et al. 
2019), including RAD21, although in one individual this 
remains uncertain (Table S6). The prevalence of holopros-
encephaly spectrum in RAD21-CdLS must remain uncertain 
as brain MRIs are typically not indicated in individuals with 
CdLS due to the burden of the procedure and lack of conse-
quences of findings for care (Kline et al. 2018).
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Development, cognition and behavior
Most data on cognition and behavior in the present cohort 
are based on subjective information provided by physicians 
and not on formal testing. Therefore, reliability remains 
uncertain. Still, all data point to a lower prevalence and 
decreased severity of ID in RAD21 patients compared to 
NIPBL and SMC1A groups: developmental milestones are 
more frequently attained, the cognitive level is estimated 
higher, and aggression and autism are less frequent. SIB, 
a hallmark of CdLS in general (Kline et al. 2018), is infre-
quent in RAD21 individuals.
Even if an IQ is normal, subtle difficulties in neuropsy-
chological domains known to be affected in CdLS (Kline 
et al. 2018) may influence cognitive performance. Periodic 
formal screening for neuropsychological and behavioral 
problems is still warranted in all individuals with RAD21 
variants, to allow for early recognition of problems and 
access to relevant support systems. In addition, formal (in-
person) assessments can prevent misdiagnoses, such as 
autism, by putting behavioral characteristics into the per-
spective of the developmental level of patients (Mulder et al. 
2019).
Natural history
The natural history data from the present study indicate that 
pregnancies and birth tend to progress normally, prenatal 
growth retardation being present in a small minority. About 
half of the patients have congenital anomalies (cleft pal-
ate; cardiac anomalies). Major limb defects have not been 
found; diaphragmatic hernia, anal atresia or choanal atresia 
occur occasionally. Patients have typically mild facial dys-
morphisms, no small hands or feet, and increased body hair 
is less apparent compared to SMC1A and NIPBL patients. 
The clinical diagnosis of CdLS may, therefore, be difficult.
Neonatal feeding is usually not problematic. Reflux is 
common but not severe. Typical development is somewhat 
slow, mainly in speech development, and physical therapy 
or speech therapy may be indicated. As they grow up, chil-
dren only occasionally develop new medical problems. Half 
of the children show a progressive but still mild growth 
delay in head circumference and height. Vision is mostly 
normal; hearing loss is found in a third of individuals and 
may require hearing devices. Most of the patients are able 
to attend regular education or education for children with 
mild cognitive disabilities. Most have some behavioral prob-
lems (mainly anxiety, ADHD or ASD) of limited severity, 
and aggression and SIB are uncommon. Not uncommonly, 
RAD21 patients are able to start a family, and some are only 
diagnosed when more severely affected offspring is recog-
nized. This indicates that careful family analysis is para-
mount in each family in which someone is diagnosed with 
a RAD21 variant.
Genotype–phenotype associations
The relatively mild phenotype of patients with RAD21 vari-
ants seems to indicate that RAD21 is not highly intolerant to 
loss-of-function, in contrast to other CdLS-associated genes 
(NIPBL, SMC1A, PDS5, WAPL, STAG2) (Gause et al. 2010). 
Supporting this, Deardorff et al. found haploinsufficiency for 
RAD21 led to approximately halved RAD21 RNA in a cell 
line from a patient with classical CdLS, while haploinsuf-
ficiency for NIPBL is often associated with a compensatory 
upregulation of RNA levels, presumably from the intact 
allele (Borck et al. 2006; Deardorff et al. 2012; Newkirk 
Fig. 2  Structural modeling of RAD21-SMC1A domain bound to the 
head domain of SMC1A/SMC3 complex. a Model for the RAD21-
SMC1A domain (residues 543–628, green) associated to the head 
domains of SMC1A (grey) and SMC3 (orange), close to the ATP 
molecule in ATPase site 1 (ATP-1) of the SMC1A/SMC3 dimer. 
Position of affected residues (Gly575, Cys585, Arg586, Gln592, 
Phe600, Leu603, Ser618 and Ala622) is indicated as red spheres. 
Locations of other important residues (Lys573, Gly575, Lys605, 
and Thr623) are indicated. Residue Cys585 is located next to resi-
due Arg586. Residue Arg586 interacts through a salt bridge with 
RAD21 residue Glu577, stabilizing RAD21-SMC1A structure. Three 
mutated residues (Gln592, Phe600, Leu603) are located in the same 
alpha-helix as key residue Lys605, predicted to maintain the correct 
positioning of SMC1A-Asn35 at ATPase site 1, putting it into con-
tact with a catalytic water molecule and, thus, allowing progression 
of the ATPase reaction, pivotal to opening of the cohesin ring and the 
cyclic process (Marcos-Alcalde et al. 2017). Variants Ser618Gly and 
Ala622Thr do not cause structural alterations. b Root mean square 
deviation (RMSD, in Angstroms) of modeled structures (WT, wild-
type, blue line; Gly575Ala, red; Cys585Arg, light purple; Arg586Gln, 
dark green; Gln592del, light blue; Phe600del, orange; Leu603Pro, 
cyan; Ser618Gly, dark purple; Ala622Thr, light green. No relevant 
differences in RMSD values demonstrable in the trajectories of the 
mutated models when compared with wild-type model and with one 
another. c Variant Cys585Arg causes the adjacent Arg586 to lose 
interaction with Glu577, and both the Arg586 and Glu577 residues 
change their position in the mutant protein by pointing towards the 
solvent, which modifies the distribution of charges in the surface of 
RAD21-SMC1A, while the new Arg585 residue is stabilized in a 
novel interaction with Glu583. d Model for variant Gln592del after 
100  ns of MD. New positions of Arg590, Lys591 and Lys605 due 
to the absence of Gln592 are indicated. Deletion of Gln592 residue 
causes adjacent Lys591 to be located in the same position as the 
missing amino acid. This situation promotes a conformational change 
in the alpha helix, causing the Lys605, which is placed in the same 
alpha helix, to move away from site 1 of the ATPase. e Model for 
variant Phe600del (green) compared to wild-type model (pink) after 
100  ns of MD. Despite the local rearrangement in the alpha helix, 
distortions of the alpha helix are not relevant as residue Leu601 is 
placed spatially in the position equivalent to the deleted Phe600 dur-
ing the MD trajectory, allowing Lys605 to remain in the same posi-
tion. f Structure of wild-type RAD21-SMC1A (left) and variant 
Leu603Pro (right) models after 100 ns of MD. Presence of mutated 
Pro603 instead of wild-type Leu603 promotes a local change in the 
bending angle of the alpha-helix in which it is located, resulting in a 
conformational change in the alpha helix that moves Lys605 out of its 
initial position close to ATPase site 1
◂
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Table 2  Comparison of clinical characteristics of present series of individuals with RAD21 variants with sufficient clinical data (cohort A) with 
those in individuals with SMC1A and NIPBL variants [adapted from (Huisman et al. 2017)]
Clinical  characteristicsa HPO ID RAD21 (n = 29) SMC1A (n = 51) NIPBL (n = 67)
N pos/N total Percentage N pos/N total Percentage N pos/N total Percentage
Sex (male/female) 15/14 52/48 14/37 27/73 34/33 51/49
Familial mutation 5/12 42 4/47 9 n/a n/a
Length at birth < − 2SD HP:0003561 2/18 22 9/31 28 32/43 74
Weight at birth < − 2SD HP:0001511 4/22 18 11/41 27 29/43 67
Prenatal head circumference < − 
2SD
HP:0000252 7/16 44 8/24 33 39/43 91
Postnatal height < − 2SD HP:0008897 10/27 37 24/38 63 37/43 86
Postnatal weight < − 2SD HP:0004325 3/26 12 14/37 38 39/43 91
Postnatal head circumference < − 
2SD
HP:0000252 16/28 57 23/36 64 54/62 87
Brachycephaly HP:0000248 8/19 42 17/42 40 44/67 66
Low anterior/posterior hairline HP:0000294/HP:0002162 14/23 61 30/43 70 57/67 85
Arched eyebrows HP:0002553 18/27 67 32/44 73 54/67 81
Synophrys HP:0000664 19/28 68 37/46 80 61/67 91
Thick eyebrows HP:0000574 20/24 83 37/46 80 61/67 91
Long eyelashes HP:0000527 21/26 81 38/45 84 65/67 97
Concave nasal ridge HP:0011120 24/29 83 20/43 47 57/67 85
Upturned nasal tip HP:0000463 19/27 70 26/46 57 58/67 87
Short nose HP:0003196 23/26 88 26/46 57 58/67 87
Long and/or smooth philtrum HP:0000343/HP:0000319 26/29 90 27/43 63 54/67 81
Thin upper lip vermillion HP:0000219 23/29 79 33/44 75 22/24 92
Thin lips, downturned corners 
mouth
HP:0002714 16/27 59 33/46 72 23/24 96
Highly arched palate HP:0000218 8/22 36 11/37 30 35/67 52
Cleft palate or submucous cleft 
palate
HP:0000175/HP:0410031 6/25 24 10/45 22 20/67 30
Widely spaced or absent teeth HP:0000687/HP:0006349 2/20 10 13/44 30 18/23 78
Micrognathia HP:0000347 8/23 35 18/45 40 50/67 75
Low-set and/or malformed ears HP:0000369/HP:0000377 14/26 54 18/45 40 45/67 67
Major limb malformation HP:0001180/HP:0009776 0/29 0 0/49 0 17/67 25
Small hands HP:0200055 5/27 19 32/45 71 53/63 84
Proximally placed thumb HP:0009623 6/18 33 18/44 41 11/20 55
Clinodactyly 5th finger HP:0004209 13/24 54 21/45 47 42/63 67
Short 5th finger HP:0009237 23/28 82 21/45 47 42/63 67
Syndactyly hands HP:0006101 1/19 5 1/37 3 4/63 6
Abnormal palmar crease HP:0010490 9/21 43 5/40 13 21/29 72
Dislocated elbow/abnormal 
extension
HP:0005021/HP:0001377 11/24 46 2/40 5 20/34 59
Small feet HP:0001773 3/27 11 29/44 66 65/67 97
Syndactyly 2nd–3rd toes HP:0004691 4/24 17 13/46 28 21/66 32
Scoliosis HP:0002650 2/20 10 4/40 10 1/42 2
Hip dislocation or dysplasia HP:0002827/HP:0001385 2/19 11 2/40 5
Ptosis HP:0000508 11/26 42 4/40 10 8/42 19
Visual impairment HP:0000505 0/24 0 20/38 53 29/66 44
Myopia ≥ − 6.00 D HP:0011003 ≤ 2/24b ≤8 11/40 28 6/40 15
Hearing loss HP:0000365 8/24 33 16/39 41 43/66 65
Seizures HP:0001250 2/22 9 20/44 45 10/66 15
Cutis marmorata HP:0000965 3/23 13 19/44 43 27/43 63
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et al. 2017). One may speculate that the effect of haploinsuf-
ficiency of RAD21 on the function of the cohesin ring can be 
compensated more effectively compared to the other cohesin 
genes. However, patients with haploinsufficiency for RAD21 
due to microdeletions or truncating variants do not differ 
markedly from those with missense variants, and nonsense-
mediated decay is not apparent although in the present series 
of patients this was not formally tested. It remains uncertain 
whether duplication of the whole gene can lead to a CdLS 
phenotype, as demonstrated for duplications in STAG2 and 
SMC1A (Baquero-Montoya et al. 2014; Mullegama et al. 
2019), as all duplications we retrieved, were either includ-
ing several other genes or pathogenicity could not be con-
firmed. No fully intragenic duplication is known to us. Small 
duplications have also been detected in apparently healthy 
controls (unpublished observations J. Howe).
In general, protein studies combined with a detailed phe-
notype allow often, but not always, to probe for RAD21 dys-
function in patients with variants of doubtful meaning. The 
phenotype in individuals with RAD21 variants is not only 
determined by the variant itself but potentially also by other 
factors: (1) variable expression of cohesin subunits and/or 
Table 2  (continued)
Clinical  characteristicsa HPO ID RAD21 (n = 29) SMC1A (n = 51) NIPBL (n = 67)
N pos/N total Percentage N pos/N total Percentage N pos/N total Percentage
Hirsutism HP:0001007 10/26 38 37/47 79 37/43 86
CNS major and minor malforma-
tions (MRI brain)
HP:0012443 2/5 40 5/43 12
Heart (major and minor) HP:0001627 9/23 39 13/44 30 18/66 27
Major malformation of gut HP:0012718 4/30 13 3/44 7 6/24 25
Diaphragmatic hernia HP:0000776 1/30 3 1/40 3 6/24 25
Gastroesophageal reflux disease HP:0002020 13/25 52 25/42 60 47/66 71
Genitourinary system  majorc HP:0000119 1/20 5 4/42 10 0/67 0
Genitourinary system minor HP:0000119 8/23 35 9/40 23 46/67 69
HPO ID human phenotype ontology identifier, CNS central nervous system
a Only features which could be compared across at least two cohorts are presented. Full clinical description with individual data are presented in 
supplementary Table S3
b 2 of the 24 cases have myopia but unspecified severity
c Uni/bilateral renal anomalies
Fig. 3  Clinical phenotype in 
RAD21 patients. Anterior–pos-
terior facial views. F family 
identification number, y age 
in years. Family numbers cor-
respond to family numbers in 
the tables. Ages are indicated 
below each picture. Intrafamilial 
variability is illustrated by the 
comparison of facial morphol-
ogy between the members of 
family F6 and of family F16. 
Interfamilial variability is 
illustrated by the comparison 
of facial morphology between 
patients F15 and F16a/b who 
harbor the p.(Arg586*) variant. 
Pictures of members of F6 and 
of F17 were republished with 
permission (Gudmundsson et al. 
2018 and Boyle et al. 2017)
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Table 3  Cognitive and behavioral characteristics of individuals with RAD21 variants with sufficient clinical data (cohort A) with those in indi-
viduals with SMC1A and NIPBL variants [adapted from (Huisman et al. 2017; Moss et al. 2017; Mulder et al. 2019)]
HP human phenotype ontology identifier
a RAD21, 8 formal test results, others physician reported data. Equivalent HP is shown between brackets
b Includes 2 adults with learning disabilities but reported normal cognitive functioning
c Including 2 moderate/severe
d Only scored if child was older than target age
e Percentage of individuals that attain the milestone before age 3 years
f RAD21: 5 formal test results, others physician-reported data
g Including 18 patients that attained the milestone late, but age unknown
h Based on formal testing
RAD21 (n = 29) SMC1A (n = 51) NIPBL (n = 67)
N pos/N total % N pos/N total % N pos/N total %
Cognitive  functioninga
 Normal cognition 3/29b 10 3/28 11 0/58 0
 Mild disability (HP:0001256) 13/29 45 6/28 21 4/58 7
 Moderate disability (HP:0002342) 4/29c 14 9/28 32 16/58 28
 Severe disability (HP:0010864) 0/29 0 6/28 21 27/58 47
 Profound disability (HP:0002187) 0/29 0 4/28 14 11/58 19
 Disability present, severity unspecified (HP:0001249) 2/29 7
 Developmental problems, too young to determine reliably 
cognitive functioning (HP:0012759)
7/29 24
Developmental  milestonesd
Sitting without support 100e 75e 54e
 Attained on target (age < 12 months) 10/10 n/a n/a
 Attained before age 3 years 10/10 18/24 28/52
 Attained later 3/24 23/52
 Not attained yet (in patients aged ≥ 5 years) 3/24 1/52
First words 100e 35e 8e
 Attained on target (age < 15 months) 6/15 n/a n/a
 Attained before age 3 years 15/15 7/20 4/53
 Attained later 4/20 16/53
 Not attained yet patients aged ≥ 5 years) 9/20 33/53
Walking without support 100e 57e ≥29e,g
 Attained on target (age < 18 months) 12/16 n/a 1/52
 Attained before age 3 years 16/16 17/30 2/52
 Attained later 9/30 12/52
 Not attained yet (in patients aged ≥ 5 years) 4/30 19/52
Delay on one or more milestone 12/16 75 18/20 90 51/52 98
Behaviorf
 Attention deficit disorder ± hyperactivity 8/23 35
 Obsessive–compulsive behavior 6/19 32 10/26h 38
 Anxiety 10/19 53
 Constant roaming 3/15 20
 Aggression 1/16 6 12/15h 80
 Self-injurious behavior 1/18 6 11/31 35 47/61 77
 Extreme shyness or withdrawal 0/17 0
 Autistic-like features 7/20 35 18/31h 56 9/13h 69
 One or more behavioral domains affected 14/25 56
587Human Genetics (2020) 139:575–592 
1 3
binding partners in different tissues; (2) variable formation 
of isoforms in different tissues; (3) modifying genes, espe-
cially of the cohesin complex (Yuan et al. 2019); (4) epige-
netic factors such as DNA methylation and gene silencing 
(Aref-Eshghi et al. 2019), exogenous influences including 
support and education, and other factors such as host-micro-
biome interactions. Exact phenotypic consequences, if any, 
of each of the above are unknown. Specifically epigenetic 
influences may be important. Genome-wide methylation 
patterns (epi-signatures) have been shown to be altered in 
CdLS (Aref-Eshghi et al. 2020). Likely, complex interac-
tions between several of the above factors play a role.
In counseling of families with RAD21 variants, the rela-
tively high frequency of familial occurrence and marked 
intrafamilial and interfamilial variability should be men-
tioned. Parental testing is warranted, even if signs or symp-
toms are apparently absent in parents, and standard testing 
of parents may further broaden the phenotype of RAD21 
variants. We suggest a cautious use of data on variants in 
molecular databases, as due to the extremely variable and 
sometimes very mild phenotype wrong conclusions may be 
drawn in classifying the variants. In case of a CdLS phe-
notype and detection of a VUS in RAD21 in which patho-
genicity cannot be determined using clinical and molecu-
lar data of the parents, we recommend testing for variants 
in other CdLS associated genes and eventually carry out 
‘open’ exome/genome sequencing to rule out variants in 
other genes.
Limitations
Although we used a broad search strategy and the present 
RAD21 cohort is the largest reported thus far, numbers are 
still small, and these preclude further statistical analyses. 
We did not consider variants from ClinVar or Decipher that 
were reportedly (likely) benign, but we expect that these 
may contain some pathogenic variants discarded based on 
an overlooked (mild) phenotype. Furthermore, many vari-
ants are reported with insufficient clinical data preventing 
such patients to be included in the present series. Especially 
morphological data are often missing, and we stress the 
importance of the use of the CdLS consensus data in evalu-
ating individuals with variants in cohesin genes (Kline et al. 
2018). Next generation sequencing-based technologies such 
as gene panels or ‘open’ exome/genome sequencing remains 
to be introduced in many countries, and we expect identifi-
cation of many additional patients with pathogenic RAD21 
variants as clinical recognition may be difficult. Finally, we 
may have an acquisition bias due to the involvement of spe-
cialists in CdLS, causing an overrepresentation of individu-
als with a CdLS phenotype.
Future
The present results demonstrate that more information on 
larger groups of individuals with RAD21 variants is needed 
to determine the complete phenotypic spectrum. CdLS char-
acteristics such as sleep disturbances and autonomic dys-
functions in individuals with RAD21 variants are still largely 
unknown. A specific issue that needs attention is the risk 
to develop cancer (incidentally reported to date in RAD21 
patients) (Deardorff et al. 2012; Minor et al. 2014). We call 
also for more detailed study of cognitive, behavioral and 
psychiatric phenotypes, as these are of utmost importance in 
clinical care. Molecular and cellular mechanisms underlying 
cognitive problems are unclear, although cohesin-mediated 
3D-organization of the genome is suggested to play a role in 
neuronal plasticity (Fujita and Yamashita 2018). Studying 
RAD21 and other cohesin components in this process could 
contribute to the search for targeted influencing of cognition 
and especially behavior in CdLS. Effects of RAD21 variants 
on cellular functioning and relationships between genotype 
and phenotype may be elucidated further by studying epi-
signatures. This may explain presently unexpected discrep-
ancies between genotype and phenotype, and even allow 
for establishing pathogenicity in individuals with uncertain 
molecular findings.
Methods
Patients
Patients were gathered using a combination of literature 
and database search and network inquiries (see Supporting 
Information). A dedicated questionnaire was used to gather 
clinical, molecular, cognitive and behavioral data. If allowed 
by the family clinical pictures were gathered for the scoring 
of facial characteristics by the senior author (RCH). If no 
clinical pictures were available to us (n = 3 in cohort A) the 
clinician-reported description of facial characteristics was 
accepted. The CdLS clinical score (reflecting the similarity 
of clinical features to those in classical CdLS) was computed 
using cardinal features (2 points each) and suggestive fea-
tures (1 point each) according to Kline et al. (2018).
Information on cognitive functioning and behavioral 
problems was derived from physician-reported data, if possi-
ble substantiated with results of formal testing. For the CdLS 
clinical score, minor criterion “ID or global DD” was scored 
positive if ID or global DD (global developmental delay; a 
combination of delay in at least 2 developmental domains) 
was present, at any age. Elsewhere in the manuscript, cog-
nitive functioning has been classified into categories based 
on DSM-5.
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To compare the RAD21 phenotype to CdLS patients with 
variants in other genes, clinical data were obtained from 
existing NIPBL and SMC1A cohorts (Huisman et al. 2017; 
Mulder et al. 2019), to which we added further information 
if needed. For comparison of features of ASD and aggres-
sion in NIPBL patients, we derived information from the 
UK cohort (Moss et al. 2017). For the item ‘autistic like 
behavior’, we compared with scores from the Social Com-
munication Questionnaire (number above cut-off for ASD); 
for the item ‘aggression’ with presence of verbal aggression, 
physical aggression or property destruction on the Challeng-
ing Behavior Questionnaire; and for ‘obsessive–compulsive 
behavior’ with the number of patients with one or more 
items of the compulsive behavior subscale of the Repetitive 
Behavior Questionnaire above clinical cutoff.
Based on the availability of clinical data, we composed 
two cohorts: cohort A with sufficient clinical data available 
on all cardinal CdLS features, and cohort B with incomplete 
clinical data. We provide an overview of excluded cases in 
Supporting Information Table S6.
Molecular studies
Among the 29 patients (22 index) of cohort A, a clinical 
diagnosis of CdLS was suspected in 13 index cases, which 
allowed detection of RAD21 variants using array compara-
tive genomic hybridization [CGH (n = 1), Sanger sequencing 
(n = 6), ‘whole’ exome sequencing (WES, n = 2), or targeted 
exome sequencing searching for variants in genes that can 
cause intellectual disability (ID-WES, n = 4)]. Confirma-
tion by Sanger sequencing of an exome result was only per-
formed if the coverage of the exome was thought to be of 
insufficient quality. The other nine index cases were detected 
through Sanger sequencing of a series of candidate genes 
after excluding a clinical diagnosis (KBG syndrome, n = 1), 
or after WES (n = 2), ID-WES (n = 3), or array CGH or SNP 
array (n = 3). All molecular studies were performed for diag-
nostic reasons, following the various national regulations, 
and for none of the patients studies were performed because 
of the current research. For describing the variants coding 
DNA reference sequence NM_006265.2(RAD21_v001) is 
used.
Structure modeling of RAD21 variants
We checked the predicted effect of all missense variants 
retrieved with the splice prediction tool of the Alamut soft-
ware (https ://www.inter activ e-bioso ftwar e.com/alamu t-visua 
l/). We proceeded with all variants which could be modelled 
regardless of their reported classification to retrieve further 
evidence for their effect (or lack of it) on protein function.
A set of three wild-type and twelve variant protein mod-
els was generated through standard homology modeling 
procedures using the SWISS-MODEL server (http://swiss 
model .expas y.org; see Supporting Information). These were 
used to study the structural effects of the missense vari-
ants located in the protein domains in contact with SMC3 
(RAD21 N-terminus; RAD21-SMC3), STAG1/2 (RAD21-
STAG) or SMC1A (RAD21 C-terminus, RAD21-SMC1A).
Molecular dynamics simulations
To analyze the putative effect of variants on the RAD21 
structure, the behavior of the 12 variant proteins were 
compared to that of wild type models by free molecu-
lar dynamics (MD) simulation for 60–100 ns (ns) (see 
Supporting Information). Movements during the trajec-
tories were continuously measured by root-mean square 
deviation (RMSD) of atomic positions. Large variations 
of RMSD values indicate notable distortions of protein 
structure due to the abnormal amino acid variant. RAD21 
domains were modeled in complex with the accompany-
ing proteins, to facilitate functional evaluation of variants 
along the MD trajectories.
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